Discovery of 9-(6-aminopyridin-3-yl)-1-(3- (trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective and orally available mTOR inhibitor for treatment of cancer

The mTOR mediated PI3K/AKT/mTOR signal transduction pathway has been demonstrated to play a key role in a broad spectrum of cancers. Starting from the mTOR selective inhibitor 1 (Torin1), a focused medicinal chemistry effort led to the discovery of an improved mTOR inhibitor 3 (Torin2), which posses...

Full description

Bibliographic Details
Main Authors: Liu, Qingsong (Author), Wang, Jinhua (Author), Kang, Seong A. (Contributor), Thoreen, Carson C. (Author), Hur, Wooyoung (Author), Ahmed, Tausif (Author), Gray, Nathanael S. (Author), Sabatini, David (Author)
Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor), Whitehead Institute for Biomedical Research (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor), Sabatini, David M. (Contributor)
Format: Article
Language:English
Published: American Chemical Society (ACS), 2012-11-01T17:44:56Z.
Subjects:
Online Access:Get fulltext